Clinical Trial Update: Phase 1/2 Study of Vascular Disrupting Agent NPI-2358 + Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating NPI-2358 in combination with docetaxel for advanced non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• NPI-2358

Snippet

Sponsor: Nereus Pharmaceuticals, Inc. | Conditions: Cancer | Phase 1, Phase 2 | Status: COMPLETED